Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenström macroglobulinemia

Blood

Volumn 120, Issue 16, 2012, Pages 3214-3221

  Hivert, Benedicte ^a   Caron, Claudine ^b   Petit, Stephanie ^c   Charpy, Cecile ^d   Fankam Siaka, Corinne ^c   Lecocq, Stephanie ^c   Zawadzki, Christophe ^b   Susen, Sophie ^b   Rusu, Manuela ^c   Duhamel, Alain ^e   Tournilhac, Olivier ^f   Goudemand, Jenny ^b   Morel, Pierre ^a,e  

^a Centre Hospitalier de LENS   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Hopital Schaffner   (France)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^e UNIV LILLE   (France)

^f UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; IMMUNOGLOBULIN M; PROTEIN PRECURSOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD VISCOSITY; BONE MARROW; BONE MARROW BIOPSY; CELL INTERACTION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MAST CELL; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VON WILLEBRAND DISEASE; WALDENSTROEM MACROGLOBULINEMIA;

EID: 84868092691     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-388256     Document Type: Article

References (41)

1. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol. 2009;27(1):120-126.
2. Stone MJ, Bogen SA. Management of hyperviscosity syndrome. Blood. 2012;119(10):2205-2208.
3. Federici AB, Budde U, Rand JH. Acquired von Willebrand syndrome 2004: International Registry-diagnosis and management from online to bedside. Hamostaseologie. 2004;24(1):50-55. (Pubitemid 38233047)
4. Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol. 2001;14(2):401-436. (Pubitemid 32677087)
5. Eby CS. Bleeding and thrombosis risks in plasma cell dyscrasias. Hematology Am Soc Hematol Educ Program. 2007: 158-164.
6. Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood. 2011;117(25):6777-6785.
7. Sadler J. Biochemistry and genetics of von Willebrand factor Annu Rev Biochem. 1998;67(1):395-424.
8. Hamilton KK, Sims PJ. Changes in cytosolic Ca2+ associated with von Willebrand factor release in human endothelial cells exposed to histamine. Study of microcarrier cell monolayers using the fluorescent probe indo-1. J Clin Invest. 1987;79(2):600-608. (Pubitemid 17009699)
9. Lorenzi O, Frieden M, Villemin P, Fournier M, Foti M, Vischer UM. Protein kinase C-delta mediates von Willebrand factor secretion from endothelial cells in response to vascular endothelial growth factor (VEGF) but not histamine. J Thromb Haemost. 2008;6(11):1962-1969.
10. Matsushita K, Yamakuchi M, Morrell CN, et al. Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosis. Blood. 2005;105(1):207-214. (Pubitemid 40053084)
11. Bonnefoy A, Hoylaerts MF. Thrombospondin-1 in von Willebrand factor function. Curr Drug Targets. 2008;9(10):822-832.
12. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994;83(8):2171-2179. (Pubitemid 24112728)
13. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood. 1996;88(8):2951-2958. (Pubitemid 26357375)
14. Denis CV, Christophe OD, Oortwijn BD, Lenting PJ. Clearance of von Willebrand factor. Thromb Haemost. 2008;99(2):271-278. (Pubitemid 351230955)
15. van Mourik JA, Romani de Wit T. Von Willebrand factor propeptide in vascular disorders. Thromb Haemost. 2001;86(1):164-171. (Pubitemid 32663949)
16. Mazurier C, Parquet-Gernez A, Descamps J, Bauters F, Goudemand M. Acquired von Willebrand's syndrome in the course of Waldenstrom's disease. Thromb Haemost. 1980;44(3):115-118. (Pubitemid 11196248)
17. Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia. 2003;9(3):303-308. (Pubitemid 36622033)
18. Mayerhofer M, Haushofer A, Kyrle PA, et al. Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein. Eur J Clin Invest. 2009;39(9):833-836.
19. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110-115. (Pubitemid 36506291)
20. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):116-120. (Pubitemid 36506292)
21. Hilbert L, Nurden P, Caron C, et al. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide. Thromb Haemost. 2006;96(3):290-294. (Pubitemid 44377811)
22. Roy A. Estimating correlation coefficient between two variables with repeated observations using mixed effects model. Biom J. 2006;48(2):286-301. (Pubitemid 43666617)
23. Therneau T, Grambsch P. Modeling Survival Data. Extending the Cox Model. New York, NY: Springer; 2000.
24. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163-4170.
25. Rajkumar SV, Hayman S, Greipp PR. Angiogenesis in Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):262-264. (Pubitemid 36506322)
26. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520-2530.
27. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advancedstage mantle cell lymphoma. Blood. 2008;111(2):558-565.
28. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res. 2007;13(10):2825-2830. (Pubitemid 46849555)
29. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol. 2001;115(1):3-12. (Pubitemid 32995086)
30. Elsawa S, Novak A, Ziesmer S, et al. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood. 2011;118(20):5540-5549.
31. Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006;17(8):1275-1282. (Pubitemid 44288218)
32. Ho AW, Hatjiharissi E, Ciccarelli BT, et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008;112(12):4683- 4689.
33. Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112(4):946-956.
34. Grutzkau A, Kruger-Krasagakes S, Baumeister H, et al. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell. 1998;9(4):875-884. (Pubitemid 28173640)
35. Horny HP, Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol. 2002;127(2):115-117. (Pubitemid 34264197)
36. Conti P, Castellani ML, Kempuraj D, et al. Role of mast cells in tumor growth. Ann Clin Lab Sci. 2007;37(4):315-322. (Pubitemid 350105931)
37. Hiromatsu Y, Toda S. Mast cells and angiogenesis. Microsc Res Tech. 2003;60(1):64-69. (Pubitemid 36055234)
38. Ware LB, Eisner MD, Thompson BT, Parsons PE, Matthay MA. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med. 2004;170(7):766-772. (Pubitemid 39298992)
39. Fu X, Chen J, Gallagher R, Zheng Y, Chung DW, Lopez JA. Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. Blood. 2011;118(19):5283-5291.
40. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E, et al. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol. 2007;137(6):560-568. (Pubitemid 46817338)
41. Starke RD, Ferraro F, Paschalaki KE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011;117(3):1071-1080.